TGF-β1/Smad3 activation contributes to persistent and aberrant ECM remodeling of VAT in obesity, and modulation of TGF-β1 activity might be an effective treatment strategy for obesity and related diabetes23,24. This evidence concerns the gene SMAD3 and obesity due to melanocortin 4 receptor deficiency.